Kythera Biopharmaceuticals

Latest Headlines

Latest Headlines

The biggest winners--and losers--in the 2015 race for new drug approvals

In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs. Now, here's the full list of new drugs approved by the FDA in 2015, in chronological order.

Kythera bags FDA approval for its double-chin-shrinking shot

Kythera Biopharmaceuticals picked up an early FDA approval for its fat-melting injected treatment, a drug now cleared to erase double chins.

Kythera's double chin injection rolls toward FDA approval

FDA reviewers took no issue with Kythera Biopharmaceuticals' drug to reduce chin fat, signing off on its efficacy ahead of a crucial panel meeting.

Kythera soars on late-stage wins for chin-fat drug

Shares of the Calabasas, CA-based biotech outfit shot up more than 25% to $42 midmorning on Tuesday after its Monday release on the results. The promise of ATX-101 could make Kythera a buyout target, an analyst from Cowen & Co. noted, and recommended buying the company's shares.

Bayer spotlights positive PhIII data for fat-busting drug

Bayer Healthcare touted upbeat data from a pair of late-stage studies of an investigational drug targeting chin fat, setting the stage for the giant to step into growing aesthetic treatment market. And the results provide a victory from Kythera, which licensed the injected drug to Bayer for markets outside the U.S. and Canada.

Top 10 biotech IPOs of 2012

After taking a beating in previous years, biotech has been hot sector on Wall Street this year. The Nasdaq Biotech Index has shot up 30% this year compared with 15% growth in the broader market. And the fact that this year's total number of biotech IPOs already matches that of 2011 indicates that there could be a growing appetite for these types of investments. But there's no indication that we're on the verge of, or will ever, return to the go-go years of the 1990s when biotechs more easily went public at lofty values. Here's the full report >>

Intercept Pharma, Kythera Bio jump out of the IPO gate

In a rare day for biotech IPOs, Kythera Biopharmaceuticals and Intercept Pharmaceuticals hit the public markets Thursday with prices at the high end of anticipated ranges and big jumps in value. It's up for debate what the huge day for the two biotech IPOs means for other drug developers angling to go public, and in some ways Kythera and Intercept appear to be unique cases in the biopharma industry.

Investors back $70M IPO for Kythera

The biotech's lead therapy, now in late-stage development, is aimed at eliminating chin fat. That may not be a big unmet medical need in the pharma world, but investors saw a big upside on demand if the drug can win approval.

IPO priced for biotech working on drug against chin fat

Kythera Biopharmaceuticals has stuck an expected price range of $14 to $16 per share on stock in the biotech group's proposed initial public offering, seeking to raise funds to advance an injected drug for elective treatments to wipe out chin fat.

Kythera files $86M IPO to support fat-busting drug

The IPO's success will hinge on the company's ability to generate some investor excitement over ATX-101, a late-stage fat-busting therapy intended to cure people of the double chin.